
Initial license payment tied to near-term contractual delivery; additional payment opportunities may arise during development, before drug approval Partner assumes assigned clinical and regulatory funding and execution, reducing Ainos' independent capital and staffing requirements Ainos retains existing platform ownership and 25% of applicable net sublicensing revenue; potential economic participation extends beyond the $10 million licensing framework HOUSTON, TX / ACCESS Newswire / September 28, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today detailed the financial and strategic benefits of the VELDONA® License Agreement announced on September 24, 2026 (the "Agreement"). Ainos expects to complete the agreed contractual delivery shortly, with an initial license fee of $600,000 payable within 15 business days after the applicable payment conditions are satisfied.










